Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 2,513 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: RAPID Clear all

Conditions: Alzheimer's Disease
Interventions: J147, Placebo; Drug
Lead sponsor: Abrexa Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Guillain-Barre Syndrome
Interventions: Efgartigimod Alfa-Fcab, Intravenous Immunoglobulin (IVIg); Drug
Lead sponsor: Chafic Karam; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Amputation
Interventions: Perturbation; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: ELECTROENCEPHALOGRAPHIC VARIANT PATTERN 1 (Disorder)
Interventions: SARA electrode, Gold cup; Device
Lead sponsor: Cleveland Medical Devices Inc; Industry
Eligibility: 12 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hiv, Substance Use Disorders
Interventions: Descovy 200Mg 25Mg Tablet, PrEP; Drug · Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Chronic Hepatitis C Infection
Interventions: GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 36
States / cities: Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more

Conditions: Psychosis, Schizophrenia
Interventions: Early Detection (ED), Usual Detection; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 16 Years to 35 Years
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: New Haven, Connecticut • Boston, Massachusetts

Conditions: Night-eating Syndrome
Interventions: Melatonin, Placebo; Dietary Supplement · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Opiate Addiction, Pregnancy, Contraceptive Behavior, Sexual Behavior
Interventions: Nexplanon (etonogestrel contraceptive implant), Standard postpartum contraceptive care; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Physiological Function in Low Oxygen Environment
Interventions: Placebo, Aminophylline, Methazolamide, Aminophylline+Methazolamide; Drug
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: SARS-CoV-2 Infection, Bacterial Respiratory Tract Infection, Viral Respiratory Tract Infection
Interventions: Not listed
Lead sponsor: Pathnostics; Industry
Eligibility: 60 Years and older
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Delaware, Ohio • Granville, Ohio • Westerville, Ohio

Conditions: Influenza
Interventions: Intravenous hyperimmune immunoglobulin (Flu-IVIG), Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 11
States / cities: San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 8 more

Conditions: Kidney Transplantation
Interventions: Myfortic; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Leukemia
Interventions: Melphalan, Thiotepa, Fludarabine; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 1 Year to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HIV, Insomnia
Interventions: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised, Resmed ApneaLink Air device (Resmed, San Diego, CA)., Quantitative Sensory testing (QST), OraQuick Advance Rapid HIV 1/2 Swab test, Cluster of Differentiation 4 (CD4) and Viral load; Diagnostic Test · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 85 Years
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cataract
Interventions: MELT-300, Midazolam alone, Ketamine alone, Placebo; Drug
Lead sponsor: Melt Pharmaceuticals; Industry
Eligibility: 55 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Rancho Cordova, California • Jacksonville, Florida • West Fargo, North Dakota

Conditions: Type1diabetes
Interventions: Regular insulin (Humulin-R), intranasal route, SipNose intranasal device; Drug · Device
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy Volunteers
Interventions: AG221; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 56 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Gonorrhoea
Interventions: Solithromycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glioblastoma, Recurrent Glioblastoma, GBM
Interventions: Niraparib, Optune, Planned surgical resection; Drug · Device · Procedure
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 22 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sedentary Lifestyle
Interventions: Health Games Field Trial; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 11 Years to 15 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Spasticity
Interventions: repetitive Transcranial Magnetic Stimulation (rTMS), Sham repetitive Transcranial Magnetic Stimulation; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Glioblastoma (GBM)
Interventions: Dynamic susceptibility contrast MRI (DSC-MRI), Cercare Medical Neurosuite (CMN) DSC-MRI-derived hypoxia maps, Varian TrueBeam; Device · Other · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Metastatic Malignant Neoplasm in the Breast, Metastatic Malignant Neoplasm in the Colon, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Rectum, Pancreatic Carcinoma
Interventions: 18F-αvβ6-BP; Drug
Lead sponsor: Julie L. Sutcliffe, Ph.D; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147

Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome

Upper Limb Loss Perturbation Response

Self Abrading Rapidly Applied Electrode Validation

PrEP at a Syringe Services Program

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.

Melatonin Treatment for Night-Eating Syndrome

Immediate Postpartum Nexplanon Placement in Opioid Dependent Women

Rapid Acclimatization to Hypoxia at Altitude

Shifts in the Respiratory Microbiome and Clinical Outcomes of SARS-CoV-2

Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)

Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State

Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation

The Impact of Insomnia on Pain in HIV

A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR)

IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase

Food Effect Study of AG-221 in Healthy Male Subjects

Genitourinary and Pharyngeal Pharmacokinetics of Solithromycin

Niraparib/TTFields in GBM

Testing Health Games for Adolescent Physical Activity

Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Post-Stroke Spasticity

Hypoxia-targeted Radiotherapy Boost for GBM

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide